ArticleScience advances2022
Influenza virus replication in cardiomyocytes drives heart dysfunction and fibrosis.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Low-replication influenza virus mediates high pathogenicity through an inflammation-driven lung-heart-brain axis in mice.Emerging microbes & infections · 2026Article
- Modeling the Exposome in Murine Cardiovascular Disease.JACC. Basic to translational science · 2026Review
- Dissecting myocardial and systemic drivers of cardiac dysfunction in the murine CVB3 myocarditis model using microRNA-guided viral detargeting.Basic research in cardiology · 2026Article
- Research progress on the association between viruses and cardiac diseases.Journal of virology · 2026Review
- Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart.Immunity · 2026Article
- MG53 in Early Skeletal Muscle Stem Cell Activation: Implications for Aged Muscle Regeneration.Cells · 2026Review
- Gasdermin E is dispensable for H1N1 influenza virus pathogenesis in mice.Microbiology spectrum · 2026Article
- IFITM3 deficiency drives SARS-CoV-2 adaptation while preserving variant-specific traits.Nature communications · 2026Article
- Large-Scale Disease-Wide Association Study Identified Predisposition Links Between Influenza and Cardiovascular Diseases.Cardiovascular toxicology · 2026Article
- Unique immune and other responses of human nasal epithelial cells infected with H5N1 avian influenza virus compared to seasonal human influenza A and B viruses.Emerging microbes & infections · 2025Article
- Chronic Diseases and Influenza Vaccines.Vaccines · 2025Review
- IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route.Vaccine · 2025Article
- Cardioprotective effects of AMPK activation in H1N1 influenza virus infection.bioRxiv : the preprint server for biology · 2025Article
- Diagnostic and Therapeutic Challenges Between Peripartum and Influenza-Induced Inflammatory Cardiomyopathy-A Case Report and Literature Review.Journal of clinical medicine · 2025Review
- The intersection of influenza infection and autoimmunity.Frontiers in immunology · 2025Review
- Innate immune control of influenza virus interspecies adaptation via IFITM3.Nature communications · 2024Article
- FBXL19 in endothelial cells protects the heart from influenza A infection by enhancing antiviral immunity and reducing cellular senescence programs.American journal of physiology. Heart and circulatory physiology · 2024Article
- Gasdermin D promotes influenza virus-induced mortality through neutrophil amplification of inflammation.Nature communications · 2024Article
- MiR-130c-5p targets the SHVVFrontiers in immunology · 2024Article
- Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.Frontiers in microbiology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiac dysfunction is a common complication of severe influenza virus infection, but whether this occurs due to direct infection of cardiac tissue or indirectly through systemic lung inflammation remains unclear. To test the etiology of this aspect of influenza disease, we generated a novel recombinant heart-attenuated influenza virus via genome incorporation of target sequences for miRNAs expressed in cardiomyocytes. Compared with control virus, mice infected with miR-targeted virus had significantly reduced heart viral titers, confirming cardiac attenuation of viral replication. However, this virus was fully replicative in the lungs and induced similar systemic inflammation and weight loss compared to control virus. The miR-targeted virus induced fewer cardiac conduction irregularities and significantly less fibrosis in mice lacking interferon-induced transmembrane protein 3 (IFITM3), which serve as a model for influenza-associated cardiac pathology. We conclude that robust virus replication in the heart is required for pathology, even when lung inflammation is severe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.